Transgender-Affirming Hormone Therapies, QT Prolongation, and Cardiac Repolarization
JAMA Network Open · 30.07.2025 · 8 (7) · e2524124
DOI: 10.1001/jamanetworkopen.2025.24124 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 30.07.2025. Verfasst von Virginie Grouthier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Universitaire de Bordeaux, Haut-Leveque Hospital, F-33604 Pessac, France. Hauptthemen laut MEDLINE: Testosterone, Transgender Persons, Estradiol, Long QT Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Transgender women (assigned male at birth) usually take antiandrogens associated with estrogens (or are castrated) to induce feminization, whereas transgender men (assigned female at birth) take testosterone to induce masculinization. However, the cardiovascular outcomes of these gender-affirming hormone therapies (GAHTs) remain poorly studied.
Objective
To examine the association between GAHT intake and cardiac repolarization alterations on electrocardiography in transgender individuals. Design, Setting, and Participants In this cohort study, data from a prospective cohort of adult transgender individuals from a single center in France were collected from January 1, 2021, to January 1, 2023. GAHT consisted of injectable testosterone in transgender men and transdermal estradiol with mostly oral cyproterone acetate as antiandrogens in transgender women. Main Outcomes and Measures Electrocardiographic features, including QTc, T-wave maximal amplitude (TAmp), and QT peak (QTp; distance between Q onset and T peak), were studied. Circulating sex hormones, including total testosterone, estradiol, progesterone, and gonadotrophins, were assessed concomitantly to electrocardiographic intake.
Results
In the overall cohort of 120 transgender individuals (mean [SD] age, 29.7 [11.9] years; 64 transgender men and 56 transgender women), mean (SD) QTc was similar between 35 transgender women receiving GAHT (406 [20] milliseconds) and 23 transgender men before GAHT (400 [16] milliseconds) but prolonged vs 41 transgender men receiving GAHT (378 [19] milliseconds) ( P < .001) or 21 transgender women before receiving GAHT (384 [21] milliseconds) ( P < .001). The start of GAHT in 15 transgender women was associated with increased QTc (mean [SD], 20 [12] milliseconds vs before receiving GAHT; P < .001) and decreased QTc in 18 transgender men (mean [SD], −17 [16] milliseconds vs before receiving GAHT; P < .001). No participant had a QTc greater than 480 milliseconds or QTc change greater than 60 milliseconds after the start of GAHT in this study. Nonlinear mixed models (eg, integrating age, calcemia, relevant circulating hormones levels, and torsadogenic drug intake) showed that QTc was associated with total testosterone in transgender men (mean [SD] estimate, −1.6 [0.6] ms/ng/mL; P = .007) and prolactin (mean [SD], 0.4 [0.1] ms/ng/mL; P < .001). In transgender women, QTc was associated with total testosterone (mean [SD] estimate, −3.5 [0.8] ms/ng/mL; P < .001). Variation of QTp and TAmp observed after the start of GAHT and associated hormonal alteration were globally associated with those observed with QTc, although in opposite directions for transgender women and transgender men. Conclusions and Relevance In this cohort study, testosterone use in transgender men was associated with QTc and QTp shortening and increased TAmp. Androgen deprivation in transgender women was associated with opposite observations. The magnitude of QTc sexual dimorphism seen in cisgender adults was also observed in the transgender population. This work highlights that potential GAHT effects on cardiac repolarization warrant attention in the exponentially increasing transgender population, which is often exposed to coprescribed drugs prolonging QTc and at risk of TdP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Universitaire de Bordeaux, Haut-Leveque Hospital, F-33604 Pessac, France.
- University of Bordeaux, Inserm U1034, Biology of Cardiovascular Diseases, Pessac, France.
- AMPS LLC, New York, New York.
- Unit for Mathematical and Computer Modeling of Complex Systems, Institut de Recherche Pour le Développement, Sorbonne University, Bondy, France.
- INSERM, Assistance Publique-Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC) 1901, Department of Pharmacology, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
Zitieren
APA
Grouthier, V., Matamala, M., Tabarin, A., Galioot, A., Couffinhal, T., Vaglio, M., Badilini, F., Prifti, E., & Salem, J. E. (2025). Transgender-Affirming Hormone Therapies, QT Prolongation, and Cardiac Repolarization. JAMA Network Open, 8(7), e2524124. https://doi.org/10.1001/jamanetworkopen.2025.24124
Vancouver
Grouthier V, Matamala M, Tabarin A, Galioot A, Couffinhal T, Vaglio M, et al. Transgender-Affirming Hormone Therapies, QT Prolongation, and Cardiac Repolarization. JAMA Network Open. 2025;8(7):e2524124. doi:10.1001/jamanetworkopen.2025.24124
BibTeX
@article{Grouthier2025,
author = {Grouthier, Virginie and Matamala, Marie and Tabarin, Antoine and Galioot, Amandine and Couffinhal, Thierry and Vaglio, Martino and Badilini, Fabio and Prifti, Edi and Salem, Joe-Elie},
title = {Transgender-Affirming Hormone Therapies, QT Prolongation, and Cardiac Repolarization},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {7},
pages = {e2524124},
doi = {10.1001/jamanetworkopen.2025.24124}
}
EUVIMED